Towards Innovation: Creating Value: Bringing The Healthcare And Lifescience World Together
Both pharma and biotechnology companies are working towards making medicines. The biotechnology industry includes hundreds of global businesses that research and develop drugs, which are complex medicines made from living cells or organisms. Traditional pharmaceutical companies create and sell drugs made from chemical- and plant-based compounds. Now the question comes HOW DO WE INNOVATE LIFE SCIENCES TO MAKE IT STRONGER?
The biotech and pharma industries continue their fast-paced digital evolution, while geopolitical and economic forces present hurdles that require a fine-tuned strategy throughout the supply chain. One segment of the drug-delivery market are advanced drug-delivery technologies, which refer to the technologies used for controlling the rate of drug release, such as modified drug-delivery technologies such as extended release (controlled and sustained release), controlled release, targeted release, delayed release, and pulsatile release.
The outbreak of Covid-19 sparked a mass movement to digital systems, and in 2021 this will continue to become increasingly popular, accelerating the growth of telemedicine as the future of healthcare. From drug discovery and development through to manufacturing, conducting virtual clinical trials and patient treatment, technology will create new opportunities at every stage of the healthcare process. When the pandemic unfolded, researchers from companies and universities around the globe were committed to speedily finding an effective vaccine.
In November 2020, several organizations announced positive results from interim analyses of their Phase III vaccine trials and in early December, the UK became the first country in the world to approve the Pfizer/BioNTech vaccine, with the first doses were administered to patients just days later.
ET Life Sciences Conclave
With the theme “TOWARDS INNOVATION: CREATING VALUE: BRINGING THE HEALTHCARE AND LIFESCIENCE WORLD TOGETHER” the virtual summit will initiate thought provoking discussions on science behind vaccine development, drug delivery, technology innovation, formulations and new scientific practices for bio pharma business growth at the time of crisis.
Customer expectations and safety has become the buzzword today for every stakeholder in the life science industry. All are making their business processes and functions automated and innovative to fuel the financial growth. We see an increasing number of pharmaceutical firms and indeed, medical device companies – are partnering and integrating with technology businesses.
Rolling out a vaccine in just a matter of months is one of the biggest achievements for the life sciences industry in history. Pharma companies had to not just research ways of treating a novel disease but also manage complex supply chains, contend with new models for engagement with healthcare professionals, manage remote workforces, and deal with the disruption to many clinical trials.
ET Life Sciences Conclave will bring together the pharmaceutical and biotech development community across countries. At this high-level scientific summit, scientists, pharmacists, and technologists from the pharma and biotechnology community will meet and discuss exciting future innovations and showcase the latest technologies in formulation and drug delivery to improve solubility, stability and bioavailability of drug, enhance the drug design and fasten the drug development process.
Chief Executive Officer
Jai Shankar Krishnan
Vice President-High Growth Markets
Managing Director, Bayer Zydus and South Asia Head
Dr. Neeta Verma
National Informatics Centre
Dr. Rana Mehta
Partner and Leader – Healthcare
Prof. S.S. Vasan
COVID-19 Project Leader, CSIRO (Australia) and Honorary Professor
University of York (UK)
Managing Director and CEO
Bharat Serums and Vaccines
Dr. Srivari Chandrasekhar
CSIR-Indian Institute of Chemical Technology (IICT)
Ministry of Science and Technology
Indian Pharmaceutical Alliance
Managing Director & Head-Human Pharma
Boehringer Ingelheim India
RPG Life sciences
|10.00 – 10.10
|Opening Address by The Economic Times
|10.15 – 10.30
Opening Keynote: Era of Covid-19 – From Virus to Vaccine – Journey so far, and the future ahead
Prof. S.S. Vasan, COVID-19 Project Leader, CSIRO (Australia) and Honorary Professor, University of York (UK)
|10.35 – 10.45
|Presentation by Jai Shankar Krishnan, Vice President – High Growth Markets, Danaher Corporation
|10:50 – 11:40
Inaugural Panel: Towards safer India: Managing Global Health Epidemics Better!
Description: Covid-19 has sent shockwaves through the world and has greatly impacted the way we function. There are many lessons this pandemic has given us. Among a plethora of messages on COVID-19 was a request to God to reboot 2020 as it has a virus. But the reality is that nations across the globe will have to reboot their thoughts and creativity to tackle the deadly spread in a structured way.
Sanjiv Navangul, Managing Director and CEO, Bharat Serums and Vaccines
Vani Manja, Managing Director & Head of Human Pharma at Boehringer Ingelheim India
|11:45 – 12:00
Keynote Address: The Digital Government Transformation – During pandemic & beyond
The pandemic has changed government priorities, forcing agency leaders to re-evaluate digital transformation strategies and plans. Some organizations are embracing digital transformation and accelerating the adoption of new technologies. In several scenarios, organizations will expand the role of digital government platforms.
Sunil Kumar, Scientist-G, National Informatics Centre
|12:05 – 12.20
Spotlight Session: “Diseases Know No Borders” – Importance & Impact of Collaborations in the fight for Life!
In a matter of a few short weeks, the disease has spread rapidly from its origins in China across the planet and has brought the globe unmercifully to its knees. Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets. The session will bring forward the discussions among leaders on the needs of collaboration, concerns and benefits.
|12:25 – 12.40
Case Study: How Life Sciences 4.0 and global pharma industry is reshaping the health care ecosystem
Gautam Khanna, Chief Executive Officer, Hinduja Hospital
|12.45 – 13.35
Panel: How technology can improve healthcare and Pharma Industry- What’s next?
Just a few months into this ‘new normal’, it is already clear that digital tech will have a pivotal role to play in ensuring that the life sciences and pharma industry continues to function to the best of its abilities, providing both healthcare practitioners (HCPs) and patients with the vital support they need. The session aims to provide an overview of the current state of digital in the sector, the value potential for digital solutions, and what’s next from here:
Dr S. Chandrasekhar, Director, CSIR-Indian Institute of Chemical Technology
Divya Rajagopal, Senior Assistant Editor, The Economic Times